Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817064 | 0.94 | EPHX2 (0.38) | MEN1KMT2AEPHX2 | |
| SCHEMBL5128701 | 0.86 | CCR1 (0.41) | MEN1KMT2ACCR1DRD2DRD4 | |
| SCHEMBL5132300 | 0.84 | CYP46A1 (0.40) | MEN1KMT2AALDH1A1EPHX2 | |
| SCHEMBL5130009 | 0.84 | MEN1 (0.46) | MEN1KMT2ACCR1DRD2DRD4 | |
| SCHEMBL5131980 | 0.83 | EPHX2 (0.43) | CCR1ALDH1A1SMN1; SMN2GRM5EPHX2 | |
| SCHEMBL5131291 | 0.81 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5131290 | 0.81 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5128012 | 0.80 | BDKRB1 (0.43) | CCR1ALDH1A1SMN1; SMN2EPHX2MAPT | |
| SCHEMBL2566064 | 0.79 | BDKRB1 (0.40) | MEN1KMT2AALDH1A1EPHX2MAPT | |
| SCHEMBL2564167 | 0.79 | BDKRB1 (0.48) | MEN1KMT2AALDH1A1EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2086935-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008046573-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | MEN1 1340/4885KMT2A 2892/4885CCR1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.